Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant965 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,240 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | recruiting | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07321197 | Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)(RECLND) | recruiting | N/A | 220 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 25, 2026 |
| clinicaltrials |
| NCT07321210 | Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)(UTLUND) | recruiting | N/A | 150 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 / Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07484022 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | recruiting | Phase 1 | 37 | Generate BiomedicinesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657325 | Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma | recruiting | — | 110 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07038733 | Investigation of Lymph Node Biology in Kidney Cancer(LN-RCC) | recruiting | N/A | 33 | Yale UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07643415 | Spinal Versus General Anesthesia in Open Simple Prostatectomy | recruiting | N/A | 80 | Hitit UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05204186 | Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence(COMORBID-AI) | recruiting | — | 500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06434350 | Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | recruiting | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646145 | Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | recruiting | Phase 3 | 718 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07029256 | Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB) | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07048457 | Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma(CONSOLIdATE-1) | recruiting | Phase 2 | 32 | Yale UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07037004 | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery | recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07524426 | Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment(LORUP) | recruiting | N/A | 248 | Umeå UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07018037 | Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma(TTV ccRCC) | recruiting | — | 20 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03747133 | SABR for Renal Tumors | recruiting | N/A | 90 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06783348 | Radiopharmaceutical Treatment of Advanced Kidney Cancer(RENALUT) | recruiting | Phase 2 | 48 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07439120 | Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors | recruiting | Early Phase 1 | 10 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06421142 | FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer | recruiting | N/A | 80 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06388720 | The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy(IMGeS) | recruiting | Phase 2 | 82 | National Cancer Center, KoreaOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07390617 | A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma | recruiting | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06949215 | 68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision(NYCRCCL) | recruiting | Phase 2 | 70 | Peking Union Medical College HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07475403 | Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07023432 | Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) | recruiting | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | recruiting | — | 150 | Oslo University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06053658 | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05184790 | LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology(LEARN) | recruiting | — | 300 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT05700461 | Drug Screening Using Novel IMD in Renal Cell Carcinoma | recruiting | Phase 1 | 20 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07581496 | T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer | recruiting | — | 35 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT07590310 | Clinical Application of CAIX-Targeted PET Imaging in Tumors | recruiting | Early Phase 1 | 3 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06586255 | Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer | recruiting | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07048496 | Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support(BCG at Home) | recruiting | N/A | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials